Janssen files its first CAR-T therapy cilta-cel in EuropeJohnson & Johnson’s Janssen unit has filed for approval of its multiple myeloma CAR-T ciltacabtagene autoleucel in Europe, Share XJanssen files its first CAR-T therapy cilta-cel in Europehttps://pharmaphorum.com/news/janssen-files-its-first-car-t-therapy-cilta-cel-in-europe/
Sanofi’s Sarclisa gains new US multiple myeloma indicationThe FDA has approved Sanofi’s Sarclisa (isatuximab) in combination with a new chemotherapy regimen for advanced multiple myeloma, Share XSanofi’s Sarclisa gains new US multiple myeloma indicationhttps://pharmaphorum.com/news/sanofis-sarclisa-gains-new-us-multiple-myeloma-indication/
FDA approves BMS’ multiple myeloma CAR-T AbecmaThe FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat Share XFDA approves BMS’ multiple myeloma CAR-T Abecmahttps://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/
NICE backs ovarian cancer and multiple myeloma combination drugsNICE has recommended funding for two cancer drug combinations for ovarian cancer and multiple myeloma. In final draft Share XNICE backs ovarian cancer and multiple myeloma combination drugshttps://pharmaphorum.com/news/nice-backs-ovarian-cancer-and-multiple-myeloma-combination-drugs/
BCMA Targeted Therapies SummitBuilt with thought leaders from Seattle Genetics, Precision Biosciences and Kite Pharma, the inaugural industry-focused BCMA Targeted Therapies Share XBCMA Targeted Therapies Summithttps://pharmaphorum.com/events/bcma-targeted-therapies-summit/
NICE reverses stance on Celgene’s Revlimid for myeloma maintenanceNHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after Share XNICE reverses stance on Celgene’s Revlimid for myeloma maintenancehttps://pharmaphorum.com/news/nice-reverses-view-of-celgenes-revlimid-for-myeloma-maintenance/
Chasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAJohnson & Johnson’s Janssen unit has filed a rolling submission for its multiple myeloma CAR-T ciltacabtagene autoleucel (cilta-cel) Share XChasing BMS, J&J files BCMA CAR-T for multiple myeloma to FDAhttps://pharmaphorum.com/news/chasing-bms-jj-files-bcma-car-t-for-multiple-myeloma-to-fda/
Janssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionJanssen has submitted a new combination regimen for its blockbuster multiple myeloma drug Darzalex for approval with the Share XJanssen combines Darzalex with COVID-19 drug in new multiple myeloma submissionhttps://pharmaphorum.com/news/janssen-combines-darzalex-with-covid-drug-in-new-multiple-myeloma-submission/
Scotland backs two myeloma drugs turned down by NICE in EnglandA north-south divide threatens to emerge in multiple myeloma in the UK, after the Scottish Medicines Consortium (SMC) Share XScotland backs two myeloma drugs turned down by NICE in Englandhttps://pharmaphorum.com/news/scotland-backs-two-myeloma-drugs-tuned-down-by-nice-in-england/
